Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 10959
Date Received: 16/12/2025
Summary:
Please provide recorded information held by NHS Lothian within the last 18 months that confirms: 1. Whether a change to the Advanced Nurse Practitioner (ANP) uniform has been approved, planned, or formally proposed; and 2. If a change has been approved or is planned, details of: o What the new or replacement uniform will be, and o The anticipated or agreed implementation timeframe; and 3. If no change is planned, confirmation of this and the most recent recorded decision stating that no change will be made.
Date of Response: 31/12/2025
View Response: 10959.pdf
Freedom of Information Request Reference: 10897
Date Received: 01/12/2025
Summary:
I would be grateful if you could provide copies of any internal guidelines, protocols, policies or standard operating procedures that relate specifically to mealtime/ dining room support in the treatment of eating disorders within your services. This includes, but is not limited to, documents that cover: • expectations and roles of staff during mealtimes • levels of supervision and support before, during and after meals or snacks • management of meal related distress, behaviours or incidents • use of any structured mealtime programmes or approaches • Nasogastric feeding or the use of oral nutrition supplements If different guidelines are used in different settings, please provide all relevant documents. For example, where your organisation has separate or adapted guidance for: • inpatient wards • day hospital or day programme services • intensive outpatient / intensive community treatment • outpatient or community services Similarly, I would also be grateful if you could provide all protocol versions, if different protocols apply to different age groups, including: • adult eating disorder services • CAMHS / children and young people’s eating disorder services • all age or transition services, if applicable
Date of Response: 31/12/2025
View Response: 10897.pdf
Freedom of Information Request Reference: 10976
Date Received: 22/12/2025
Summary:
I'm writing to request some information under the Freedom of Information (Scotland) Act 2002 regarding the vehicles currently in use by Lothian NHS Scotland, For each vehicle, please provide the following information: -Vehicle Make/model and body colour -Date of first registration with the DVLA (in format DD/MM/YYYY) -Date of the next MOT in format DD/MM/YYYY (where applicable - I am aware that vehicles under three years old are exempt from MOT testing)
Date of Response: 24/12/2025
View Response: 10976.pdf
Freedom of Information Request Reference: 10925
Date Received: 09/12/2025
Summary:
Could you please provide the antenatal CTG guidance in place currently, as well as in August 2022? The guidance should cover CTGs throughout pregnancy.
Date of Response: 24/12/2025
View Response: 10925.pdf
Freedom of Information Request Reference: 10895
Date Received: 28/11/2025
Summary:
Under Freedom of Information can you please advise the cost you attribute to having a hospital bed available ( an average of all disciplines please?) on a 24 hour basis?
Date of Response: 24/12/2025
View Response: 10895.pdf
Freedom of Information Request Reference: 10894
Date Received: 28/11/2025
Summary:
1. Does the aseptic unit at your organisation employ vial-sharing for durvalumab (Imfinzi)? 2. In the past 12 months was durvalumab (Imfinzi) administered as the following actual doses? 1,500 mg 10 mg / kg 20 mg / kg 3. In the past 12 months was durvalumab (Imfinzi) made up for administration to patients at an on-site aseptic unit? 4. In the past 12 months was durvalumab (Imfinzi) made up for administration to patients at an external aseptic unit? 5. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of durvalumab (Imfinzi) in the past 12 months. 6. How many patients were treated with durvalumab (Imfinzi) between Jul and Sep 2025, or latest 3 months for which data is available? 7. How many patients were treated with durvalumab (Imfinzi) within each of bands in the national dose banding table between Jul and Sep 2025? 8. How many patients were treated with durvalumab (Imfinzi) for the following types of cancer between Jul and Sep 2025, or latest 3 months for which data is available? Non-small Cell Lung Cancer Biliary Tract Cancer Small Cell Lung Cancer Hepatocellular Carcinoma Endometrial Cancer Muscle Invasive Bladder Cancer Other (please specify) 9. Does the aseptic unit employ vial-sharing for trastuzumab deruxtecan (Enhertu)? 10. In the past 12 months was trastuzumab deruxtecan (Enhertu) administered as the following actual doses? 6.4 mg / kg 5.4 mg / kg 4.4 mg / kg < 4.4 mg / kg 11. In the past 12 months was trastuzumab deruxtecan (Enhertu) made up for administration to patients at an on-site aseptic unit? 12. In the past 12 months was trastuzumab deruxtecan (Enhertu) made up for administration to patients at an external aseptic unit? 13. Please list the names of external hospitals or hospitals within the Trust that have supplied your organisation with made-up batches of trastuzumab deruxtecan (Enhertu) in the past 12 months. 14. How many patients were treated with trastuzumab deruxtecan (Enhertu) within each of bands in the national dose banding table between Jul and Sep 2025?
Date of Response: 24/12/2025
View Response: 10894.pdf
Freedom of Information Request Reference: 10892
Date Received: 27/11/2025
Summary:
1. What is the name of your Medics Appraisals software provider? (None if software not used) 2. What is the name of your second Medics Appraisals software provider? (If you have more than one software provider) 3. When did the contract for your Medics Appraisals software provider start? (dd/mm/yyyy) (None if software not used) 4. When does the contract for your Medics Appraisals software provider expire? (dd/mm/yyyy) (None if software not used) 5. When did the contract for your second Medics Appraisals software provider start? (dd/mm/yyyy) (If you have more than one software provider) 6. When does the contract for your second Medics Appraisals software provider expire? (dd/mm/yyyy) (If you have more than one software provider) 7. What was the Trust's total spend on Medics Appraisals fees in 2024 – not incl. implementation? 8. What was the Trust's total spend on Medics Appraisals fees in 2025 – not incl. implementation?
Date of Response: 23/12/2025
View Response: 10892.pdf
Freedom of Information Request Reference: 10889
Date Received: 27/11/2025
Summary:
Please will you send me a list of Edinburgh schools included in the flu immunisation programme, and the date(s) the vaccine was administered to pupils at each school. Please send this information for 2021, 2022, 2023, 2024 and 2025.
Date of Response: 23/12/2025
View Response: 10889.pdf
Freedom of Information Request Reference: 10888
Date Received: 26/11/2025
Summary:
Can you please provide an update on your Trust’s Infrastructure, including aspects of Networking, Virtualisation, and Cloud? The questions are in the attached spreadsheet, which I would be grateful if you could fill in.
Date of Response: 24/12/2025
View Response: 10888.pdf
Freedom of Information Request Reference: 10884
Date Received: 26/11/2025
Summary:
Please could you provide the following details for any current contract(s). Contract title Start date End date Current supplier Total Contract Value Framework used (if any)
Date of Response: 23/12/2025
View Response: 10884.pdf
Freedom of Information Request Reference: 10883
Date Received: 26/11/2025
Summary:
I wish to make a Freedom of Information Request for the number of patients currently waiting for care at home packages & the combined number of hours.
Date of Response: 24/12/2025
View Response: 10883.pdf
Freedom of Information Request Reference: 10880
Date Received: 25/11/2025
Summary:
I would like to request the following publicly held information relating to the financial accounts of NHS Lothian. • I would like to request the total amount of outstanding debt that is currently owed to NHS Lothian. • I would like to confirm that any such debt is not classed as “accounts payable” and does not accrue interest. • I would like to request the total outstanding value of dept owed to NHS Lothian that exceeds short-term liability of 30 days. • I would like to request how much of this outstanding debt is owed by staff due to overpayments made to them. • I would like to request how much of this debt has been accrued as a result of overseas patients not being charged appropriately for their treatments or care.
Date of Response: 24/12/2025
View Response: 10880.pdf
Freedom of Information Request Reference: 10865
Date Received: 20/11/2025
Summary:
We request under FOISA that you provide, (in a machine readable format, preferably Microsoft Excel or CSV) the following information in respect of suppliers which were not paid in within 30 days for the period starting 1 April 2019 to the date of this request: Supplier Name Invoice Date Invoice Received Date Invoice Due Date Gross Invoice Value Payment Date Payment Terms Late Payment Compensation or Interest Paid (if any)
Date of Response: 24/12/2025
View Response: 10865.pdf
Freedom of Information Request Reference: 10872
Date Received: 24/11/2025
Summary:
Please provide the following information regarding payroll overpayments and pay errors across NHS Lothian, including all staff categories (e.g., clinical, administrative, and executive): 1. The total financial amount (in GBP) lost due to overpayments or pay errors in each of the last five financial years (2020/21 to 2024/25). Please break this down by year.2. A breakdown of the types of overpayments or pay errors contributing to these totals (e.g., incorrect salary grading, overtime miscalculations, duplicate payments, or other categories), including the financial value for each type where possible. 3. The total amount recovered from these overpayments or pay errors in each of the last five financial years (2020/21 to 2024/25), broken down by year. 4. Any internal reports, audits, or policies related to preventing or addressing payroll overpayments/pay errors, published or completed in the last five years (please provide copies or links if available).
Date of Response: 23/12/2025
View Response: 10872.pdf
Freedom of Information Request Reference: 10724
Date Received: 13/10/2025
Summary:
I am requesting the following information held by NHS Lothian concerning oncology treatment delays, cases where Functional Neurological Disorder (FND) was initially diagnosed but later found to be cancer, and discharge safety regarding prophylactic anticoagulation. Time periods requested: • Most recent complete year: 2024 • Ten-year look-back: 2014 (or nearest available year) • Optional: annual breakdown 2020–2024, if available without undue burden ________________________________________ A. Oncology – Biopsy and Treatment Delays 1. Average, median, and maximum turnaround time from biopsy to pathology report. 2. Number of patients whose chemotherapy or treatment schedule was delayed due to biopsy or pathology turnaround. 3. Total number of biopsies processed and number of pathologists and lab technicians on staff during these periods. ________________________________________ B. Neurology / FND Misdiagnosis Impacting Cancer Care 1. Number of patients initially diagnosed with FND who were later confirmed to have cancer. 2. Diagnostic process prior to FND diagnosis, for example in a patient presenting with limited or absent sensation in the lower limbs (paraplegic): o Application of the Three Rules: 1. Rule out structural or organic neurological disease 2. Rule out systemic/metabolic causes 3. Rule out drug/toxin-related causes o Tests that would normally be performed according to standard guidance, including MRI, CT, EMG/nerve conduction studies, blood/metabolic panels, lumbar puncture, and specialist referrals. o Indicate which of these tests are routinely performed prior to confirming FND. 3. Typical steps taken before confirming FND – e.g., referrals, follow-up appointments, monitoring procedures. 4. Delays caused in cancer care: Average, median, and maximum time from initial presentation to: o FND diagnosis o Cancer diagnosis o Start of appropriate treatment 5. Safeguards to prevent misdiagnosis: Policies or standard procedures in place to reduce the risk of incorrectly diagnosing FND when a serious condition such as cancer may be present. ________________________________________ C. Discharge and Blood Thinner Protocols 1. For patients who were immobilised or had limited mobility during a hospital stay (e.g., due to neurological symptoms, misdiagnosed FND, or cancer treatment): o Number of patients discharged without prophylactic anticoagulants (blood thinners) despite being at risk of thromboembolism. o Policies or guidance on prescribing blood thinners at discharge for patients at risk of clots. o Instances where GPs were asked to continue or start prophylactic blood thinners post-discharge, and whether refusals occurred. 2. Any recorded delays or complications (e.g., blood clots) linked to the absence of prophylactic anticoagulation at discharge.
Date of Response: 24/12/2025
View Response: 10724.pdf
Freedom of Information Request Reference: 10119
Date Received: 19/05/2025
Summary:
Under FOI, I am requesting the following: • Total costs incurred for calendar years 2021, 2022, 2023, 2024, and 2025 to the present relating to RAAC remediation, including: o Surveys, investigations, or assessments o Temporary mitigation (e.g. propping, partial closures, relocations) o Repairs, remedial work, or reconstruction o Other associate costs Please also provide a breakdown of cost figures by building type (e.g housing, schools etc) ________________________________________ 3. Total Projected or Estimated Future Costs including but not limited to: • Estimated or projected future costs for the full remediation, removal, or rebuilding of RAAC-affected buildings. • Associated indirect costs (e.g. temporary facilities, decanting, service relocations). • Costs of assessment ________________________________________ 4. Funding and Financial Support • Details of any funding received or allocated specifically for RAAC-related work, including: o Source of funding (e.g. Scottish Government, capital budgets) o Amount and date received 5. Details of any funding requests which have been made but refused (for example to the Scottish Government)
Date of Response: 02/12/2025
View Response: 10119.pdf
Freedom of Information Request Reference: 10954
Date Received: 11/12/2025
Summary:
Request in relation to CCTV footage.
Date of Response: 18/12/2025
View Response: 10954.pdf
Freedom of Information Request Reference: 10918
Date Received: 08/12/2025
Summary:
Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease. Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products • Marstacimab • Cevenfacta Q3. For patients treated with Advate in the last three months, please provide: • The number of haemophilia A patients treated prophylactically • The number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds) Q4. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY? • Altuvoct • Advate • Adynovi • Elocta • Esperoct • Factor Eight Inhibitor Bypass Activity (FEIBA) • Hemlibra (standalone) • Hemlibra in combination with any Factor VIII • NovoEight • NovoSeven RT • Nuwiq • Obizur • Refacto AF • Any other products • Marstacimab • Cevenfacta
Date of Response: 19/12/2025
View Response: 10918.pdf
Freedom of Information Request Reference: 10913
Date Received: 05/12/2025
Summary:
I notice from the Board’s web site that there has been a service redesign [around May 2025] of part of the Board’s audiology services [https://services.nhslothian.scot/audiology/test/ ]. I am writing to ask the Board to provide me, in accordance with the Freedom of Information legislation, with a copy of the Equality Impact Assessment the Board is required to carry out when redesigning services.
Date of Response: 22/12/2025
View Response: 10913.pdf
Freedom of Information Request Reference: 10902
Date Received: 02/12/2025
Summary:
Question 1. How many patients were treated in the last 4 months (August to November 2025) by the dermatology department with each of the following products: •Abrocitinib •Acitretin •Alitretinoin •Azathioprine •Baricitinib •Ciclosporin •Dupilumab •Lebrikizumab •Methotrexate •Mycophenolate mofetil •Pimecrolimus •Phototherapy (UVB or PUVA) - for Atopic Dermatitis only •Tacrolimus ointment •Tralokinumab •Upadacitinib •Nemolizumab Question 2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department •Abrocitinib •Baricitinib •Dupilumab •Lebrikizumab •Tralokinumab •Upadacitinib •Nemolizumab Question 3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group: •6 months to 5 •Age 6-11 •Age 12-17 •Age 18 and above
Date of Response: 19/12/2025
View Response: 10902.pdf
Freedom of Information Request Reference: 10899
Date Received: 01/12/2025
Summary:
For the financial year 2024/25 (April 2024 – March 2025), please provide the following information relating to outsourced reporting services only (excluding any outsourced scanning): 1. What was the total value (£) of radiology reporting work outsourced to private tele-radiology providers? 2. What was the total volume (number of reports) of radiology reporting work outsourced to private tele-radiology providers? 3. Of the outsourced reporting activity, how many were: o MRI reports? o CT reports? o Plain Film reports? 4. Which private tele-radiology companies were used by the Trust during this period? 5. Who holds responsibility within the Trust for overseeing outsourced radiology reporting? Please provide: o Name o Job title o Division/department
Date of Response: 03/12/2025
View Response: 10899.pdf
Freedom of Information Request Reference: 10898
Date Received: 01/12/2025
Summary:
1/What is the required frequency for statutory BLS training? 2/What incentives or measures has the trust adopted to encourage annual BLS training for medical professionals with patient facing duties ( no pay progression if mandatory training not completed, departmental sessions, ESR alerts, managerial supervision of mandatory training etc)? 3/ Does the organisation require resus teams to have Advanced Life Support training?
Date of Response: 19/12/2025
View Response: 10898.pdf
Freedom of Information Request Reference: 10891
Date Received: 27/11/2025
Summary:
Request in relation to personal information.
Date of Response: 27/11/2025
View Response: 10891.pdf
Freedom of Information Request Reference: 10886
Date Received: 26/11/2025
Summary:
Haemophilia A Q1. In the past 12 months [latest 12 months available], how many patients have been diagnosed with the each of the following conditions in your Trust: Haemophilia A Acquired Haemophilia A (AHA) Congenital Haemophilia A with inhibitors CHAwI) Q2. In the last twelve months[latest 12 months available], how many pts with Haemophilia A, have been treated with each of the following products in your Trust: Factor Eight Inhibitor Bypass Activity (FEIBA) Hemlibra (standalone) Hemlibra in combination with NovoSeven RT Hemlibra in combination with Cevenfacta NovoSeven RT Obizur Cevenfacta Q3. In the last twelve months[latest 12 months available], how many patients with Acquired Haemophilia A, have been treated with each of the following products in your Trust: Factor Eight Inhibitor Bypass Activity (FEIBA) NovoSeven RT Obizur Cevenfacta Q4 In the last twelve months[latest 12 months available], how many pts with Congenital Haemophilia A with Inhibitors have been treated with each of the following products in your Trust? Factor Eight Inhibitor Bypass Activity (FEIBA) Hemlibra (standalone) Hemlibra in combination with NovoSeven RT Hemlibra in combination with Cevenfacta Hemlibra in combination with FEIBA Helimbra in combination with Factor VIII NovoSeven RT Obizur Cevenfacta Prothrombin Complex Concentrate (PCC) Q1. What is the total Prothrombin Complex Concentrate usage in International Units (IUs) for your Trust over the last 12 months [latest 12 months available] for each of the products below in your Trust? Prothromplex Beriplex Octaplex Q2: Can you share the Prothrombin Complex Concentrate usage in International Units for your Trust in the last 12 months [latest 12 months available] within each of the following departments, and which PCC is used? Prothromplex Beriplex Octaplex Departments Cardio-speciality General Medicine General surgery Haematology Emergency care Any other
Date of Response: 17/12/2025
View Response: 10886.pdf
Freedom of Information Request Reference: 10885
Date Received: 26/11/2025
Summary:
HAE: Q1. In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]: Berinert (Human C1-esterase inhibitor) Cinryze (Human C1-esterase inhibitor) Orladeyo (Berotralstat) Takhzyro (Lanadelumab) Ruconest (Recombinant human C1-esterase inhibitor) Firazyr (Icatibant injection) Icatibant - any brand except Firazyr IG: Q2. In the past 3 months how many patients have received the following treatment for any disease: Octagam Gamunex Intratect Kiovig Gamten Panzyga Xembify Cuvitru Cutaquig Hyqvia Q3: In the past 3 months, how many patients have received any immunoglobulin treatment for the following diseases: Primary immunodeficiency (PID) Secondary immunodeficiency (SID) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Date of Response: 19/12/2025
View Response: 10885.pdf
Freedom of Information Request Reference: 10882
Date Received: 25/11/2025
Summary:
1. The total amount paid by NHS Lothian in rent and associated fees to the owners or operators of: o The Royal Infirmary of Edinburgh (since its opening at Little France in 2003), and o The Royal Hospital for Sick Children (since its opening at Little France in 2021). 2. Please include any fees or payments made prior to the opening of these hospitals, such as during construction or commissioning phases. 3. Provide a breakdown of the figures by financial year, and if possible, specify: o Rent payments o Service charges or other fees o Any other contractual payments related to the use of these facilities 4. Copies of the contracts or agreements between NHS Lothian and the owners/operators of these hospitals, including any variations or amendments made since the original agreements.
Date of Response: 19/12/2025
View Response: 10882.pdf
Freedom of Information Request Reference: 10881
Date Received: 25/11/2025
Summary:
Please provide the following information for the past three full calendar years 2022, 2023, 2024 and for 2025 to date. Q1. The number of patients referred for mental health or psychological support where a dermatology or skin condition was recorded in any part of the referral record including diagnosis fields, contributing factors, referral notes or coding flags. If exact figures cannot be extracted, please provide any available count or estimate. Q2. If held, please provide any available breakdown of these referrals by age or age band. For example children, young people, adults or older adults, or alternative groupings used in your reporting systems. Q3. The number of psychodermatology referrals recorded in each year, if your Health Board records this term or pathway. If psychodermatology is not coded separately or not offered, please confirm this and provide any available information on cases where dermatological conditions were linked to mental health support. Q4. The total number of dermatology referrals recorded in each year, or any equivalent activity data such as dermatology outpatient attendances.
Date of Response: 19/12/2025
View Response: 10881.pdf
Freedom of Information Request Reference: 10879
Date Received: 25/11/2025
Summary:
1. I am writing to request a detailed breakdown of Medical Agency spend for the following periods: • 1st April 2024 – 31st March 2025 • 1st April 2025 – 31st October 2025 Please provide the data in Excel format, including the following details for each month: • By grade, specialty, and sub-specialty • For each hospital • Split by framework and non-framework agencies 2. I am also requesting a detailed breakdown of Medical Bank spend for the following periods: • 1st April 2024 – 31st March 2025 • 1st April 2025 – 31st October 2025 Please provide the data in Excel format, including the following details for each month: • By grade, specialty, and sub-specialty • For each hospital • Split by framework and non-framework agencies
Date of Response: 16/12/2025
View Response: 10879.pdf
Freedom of Information Request Reference: 10878
Date Received: 25/11/2025
Summary:
“On a renal transplant unit recently in a major NHS hospital, two trans people insisted on having beds [in side rooms], which the current faulty code allows, and two transplant patients were moved on to the general ward, as a result of which one patient lost his new kidney and nearly died.” Question: Please search your records for the period 1st October 2024 to 8th of November 2025 and advise if the circumstances outlined above occurred in your hospital.
Date of Response: 16/12/2025
View Response: 10878.pdf
Freedom of Information Request Reference: 10877
Date Received: 25/11/2025
Summary:
Q1. Does your trust treat Polycythaemia Vera (ICD10 code D45)? If no, please provide the name of the trust that you refer Polycythaemia Vera patients to? Q2. How many patients were initiated on Ruxolitinib (Jakavi) the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months) •Myelofibrosis (ICD10 code D47.4) •Polycythaemia Vera (ICD10 code D45) Q3. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months) •Momelotinib •Fedratinib Q4. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with? •Hydroxycarbamide •Interferon therapy
Date of Response: 16/12/2025
View Response: 10877.pdf
Freedom of Information Request Reference: 10876
Date Received: 24/11/2025
Summary:
Request relation to access record.
Date of Response: 15/12/2025
View Response: 10876.pdf
Freedom of Information Request Reference: 10875
Date Received: 24/11/2025
Summary:
Please could you provide the following information for all hospitals within your Trust that perform spinal surgery. 1. What brand of spinal operating tables your Trust uses for spinal surgery (for example Allen Spinal system, Modular tables system, Jackson table, Trios system or ProAxis system) 2. The age of these tables, or year they were installed 3. The cost of this device 4. The serial number of each table 5. Which hospital specifically the table is in
Date of Response: 19/12/2025
View Response: 10875.pdf
Freedom of Information Request Reference: 10874
Date Received: 21/11/2025
Summary:
I would appreciate it if you could provide the following details for each vehicle: Vehicle Make and Model Registration Mark of each motor vehicle (VRM) Date of acquisition Date of disposal (if applicable) for vehicles decommissioned between 2020 and 2025
Date of Response: 15/12/2025
View Response: 10874.pdf
Freedom of Information Request Reference: 10873
Date Received: 17/11/2025
Summary:
please provide for your Bank workforce for FY 2024/25 (or the most recent 12 months): 1. Do you outsource payroll for Bank workers? If yes, name of provider. 2. Your fee model for Bank payroll (e.g., per payslip, per hours processed, per timesheet, % of gross pay). 3. The fee level actually paid (e.g., £ per payslip / £ per hour / £ per timesheet / %). 4. Average number of Bank payslips per pay period and pay frequency (weekly/monthly). 5. Any additional charges (off-cycle payments, corrections, pension retros, RTI re-submissions). 6. If Bank payroll is delivered in-house, please confirm your internal cost per payslip (or best estimate) for Bank staff. Please provide any available contract end dates.
Date of Response: 12/12/2025
View Response: 10873.pdf
Freedom of Information Request Reference: 10870
Date Received: 21/11/2025
Summary:
The training undertaken by School Nurses is a Post Graduate Diploma which contains Masters level modules but it is not a full Masters Degree. Based on the qualification and also the duties and responsibilities of the role, the Matching Panel awarded a level 6 KTE." I interpret this to mean that "based on the qualification [of not having a full Masters Degree]", in part, the NHS Lothian Specialist School Nurse Job was awarded level 6 KTE and not level 7 KTE. If this was partially "based on the qualification", where in the national standards of Job Evaluation, the NHS Employers Job Evaluation, does it make mention of the requirement to have "a full Masters degree"? I want you to quote the rule that NHS Lothian is following in basing this decision, in part, on the qualification. NHS Lothian Specialist School Nurses are required to hold a Masters level qualification and the NHS Employers Job Evaluation Handbook clearly states that this should be evaluated at level 7 KTE. If NHS Lothian states that a job is awarded a certain job evaluation level "based on the qualification" then it must be able to quote the job evaluation rule that mentions that qualification. Where in the Job Evaluation handbook, that NHS Lothian claims to follow, does it mention the requirement to have "a full Masters degree". Why does the FOI response mention "a full Masters Degree" when this is never mentioned in the Job Evaluation rules?
Date of Response: 05/12/2025
View Response: 10870.pdf
Freedom of Information Request Reference: 10869
Date Received: 20/11/2025
Summary:
What is the average length of time that T1 diabetic adults & children in the catchment area of NHS Lothian must wait between appointments with their consultant?
Date of Response: 15/12/2025
View Response: 10869.pdf
Freedom of Information Request Reference: 10868
Date Received: 20/11/2025
Summary:
For each of the last seven financial years (for example: 2018/19, 2019/20, 2020/21, 2021/22, 2022/23, 2023/24 and 2024/25, or the last seven financial years for which you hold data), please provide: Total expenditure a. The total annual expenditure on translation and interpretation services. b. Please confirm whether these figures include: Face-to-face interpreters Telephone interpreting Video-remote interpreting British Sign Language (BSL) interpreting Written translation of documents and patient information Any other communication support services (please specify) Breakdown by service type For each of the same financial years, please provide the annual expenditure broken down (where recorded) into: a. Face-to-face spoken language interpreting b. Telephone interpreting c. Video-remote interpreting d. BSL or other sign language interpreting e. Written translation (e.g. patient letters, leaflets, consent forms) f. Any other distinct categories you use internally (please specify). Breakdown by language For each financial year, please provide any breakdown you hold of expenditure by language. If a full language-by-language breakdown is not readily available within the FOISA cost limits, please provide: a. The top 10 most-used languages by expenditure in each year, with spend for each; or b. The most granular language breakdown you hold in existing reports or management information. Breakdown by provider For each financial year, please provide any breakdown you hold of expenditure by provider/supplier, including: a. The name of each external provider of translation/interpreting services; and b. The total annual amount paid to each provider. If you use internal/in-house interpreters or translators, please state this and, where recorded, provide the annual cost of in-house provision (e.g. staff costs, where these are separately identified in your records or management reports). Volumes / activity data For each financial year, please provide any activity data you hold, including (where recorded): a. The total number of interpreting appointments / assignments arranged (face-to-face, telephone, video-remote) – ideally broken down by type. b. The total number of documents translated (or, if you record it differently, any other available measure of volume such as number of translation jobs or word count). If you do not hold this information in a reportable format, please confirm that this is the case. Contracts and procurement arrangements Please provide: a. Details of any current contracts or framework agreements for translation and interpretation services, including: Name of contractor(s) Contract start and end dates (including any extension periods) Whether the contract is call-off from a national framework (and, if so, which one) b. The estimated or maximum contract value for each contract, where this information is held.
Date of Response: 15/12/2025
View Response: 10868.pdf
Freedom of Information Request Reference: 10867
Date Received: 20/11/2025
Summary:
1. How many Agency shifts were advertised by this health board in NHS hospitals in 2025/26 so far? Please include figures for 2024/25 as well. Please break this down into Nursing and Midwifery, as well as Medical and Dental. 2. In relation to Question 1, how many of these shifts were successfully filled? 3. Please provide the overall spend so far on agency staff so far in 2025/26. Please include figures for 2024/25. Please break this down into Nursing and Midwifery, as well as Medical and Dental. 4. How many Bank shifts were advertised by this health board so far in NHS hospitals in 2025/26? Please include figure for 2024/25. Please break this down into Nursing and Midwifery, as well as Medical and Dental. 5. In relation to Question 4, how many of these shifts were successfully filled? 6. Please provide the overall spend so far on bank staff in 2025/26. Please include figures for 2024/25. Please break this down into Nursing and Midwifery, as well as Medical and Dental.
Date of Response: 15/12/2025
View Response: 10867.pdf
Freedom of Information Request Reference: 10866
Date Received: 20/11/2025
Summary:
Has your trust used any Insourcing Companies in the last 12 months? If so who were they? What is the total spend on Insourcing during this period (12 months). Breakdown of departments/specialties you have used Insourcing including breakdown of spend for each department. Are there any current tenders out with the trust to use Insourcing? If so what departments specifically?
Date of Response: 12/12/2025
View Response: 10866.pdf
Freedom of Information Request Reference: 10864
Date Received: 19/11/2025
Summary:
Qn: Please can you confirm the histopathology outsourcing information for the period November 2024 to October 2025 inclusive: Overall Wet lab work (plus reporting) outsourced Glass slide reporting outsourced Digital slide reporting outsourced Qn: Please confirm which outsourcing providers were used in the period and their contract end dates, plus any minimum activity or exclusivity commitment: Provider name Contract end date Minimum activity or exclusivity commitment Qn: Please can you confirm the histopathology outsourcing information for the period November 2024 to October 2025 inclusive by provider: Qn: Please confirm which specialisms you outsourced over the period November 2024 to October 2025 inclusive Qn: Please confirm your total histopathology activity by year: Qn: Please confirm your spend on histopathology locum staff cover over the period November 2024 to October 2025 inclusive, split by consultant pathologist and lab staff: Qn: Please confirm what % of your histopathology work was reported digitally over the period August 2025 to October 2025 inclusive, excluding outsourced reporting Qn: Please confirm the histopathology IT applications in use: PACS / Imaging management system LIMS (or equivalent) Scanner manufacturer(s) Qn: Please confirm the volume of any specific histopathology reporting (post-wet lab) backlog you have now? Qn: Please confirm the volume of any specific histopathology dissection backlog you have now?
Date of Response: 12/12/2025
View Response: 10864.pdf
Freedom of Information Request Reference: 10863
Date Received: 19/11/2025
Summary:
1. Within your Trust/ Health Board, where are patients (aged 2yrs +) with a diagnosis of Spinal Muscular Atrophy referred to for treatment? 2. How many patients with Spinal Muscular Atrophy have been referred in: A. The last 12 months? (or the latest 12 months of data you have available) B. The last 5 years? Could you please split this out into SMA type if possible ( Type 0, 1, 2, 3, 4) – (see attached ICD-10 codes) 3. If your Trust/ Health Board receives referrals, where are these referrals made from? 4. How many patients return to local care for continued treatment once referred to a specialist centre? 5. If you have a treating centre for Spinal Muscular Atrophy in your trust, what is the average length of stay (or annual bed days) of patients being treated?
Date of Response: 17/12/2025
View Response: 10863.pdf
Freedom of Information Request Reference: 10862
Date Received: 19/11/2025
Summary:
Please provide the following information for each financial year from 2018/19 to 2024/25 inclusive for your Health Board and, where possible, by pathology discipline (for example: Haematology, Biochemistry, Microbiology, and Histopathology): Total pathology spend (overall expenditure on pathology services) Total direct non-pay costs (consumables and reagents) Total direct pay costs (staff expenditure), and segmented if possible by: Contract type: substantive, bank, agency Band: Band 2, band 3; clinical non clinical Other indirect costs (for example, maintenance, estates, overheads) Total volume of pathology tests performed Total workforce FTE numbers, segmented if possible by: Contract type: substantive, bank, agency Band: Band 2, band 3; clinical non clinical
Date of Response: 16/12/2025
View Response: 10862.pdf
Freedom of Information Request Reference: 10861
Date Received: 19/11/2025
Summary:
Please, for the past five years, can you tell me how many data breaches you have recorded. This should be for 2020, 21, 22, 23, 24, and for the year to date for 2025. If you record them in another time period, please use this but provide the past five years worth of data. Using the same breakdown, please can you inform me how much, if anything, you have paid out in fines and/or compensation. Please state these figures separately. Finally, please can you give me a brief explanation of each incident and how many people it affected.
Date of Response: 12/12/2025
View Response: 10861.pdf
Freedom of Information Request Reference: 10859
Date Received: 19/11/2025
Summary:
1. How many adults are currently waiting for a new patient, first appointment for assessment and treatment of hearing loss? 2. How many adult patients are currently waiting for a follow-up or aftercare appointment for assessment and treatment of hearing loss? 3. How many adult patients are overdue for a follow-up or aftercare appointment for hearing loss services? 4. What is the current average and longest waiting time for a new patient first appointment for assessment and treatment of hearing loss? 5. If possible please provide an aged profile of the waiting list by number of weeks waiting. 6. What is the current average and longest waiting time for a follow-up or aftercare appointment for assessment and treatment of hearing loss? 7. If possible please provide an aged profile of the follow-up and aftercare waits list by number of weeks wating) 8. How many adults are currently waiting for an appointment for ear wax removal? 9. What is the current average and longest waiting time for a new patient referral for ear wax removal? 10. If possible please provide an aged profile of ear wax removal wait list by number of weeks wating)
Date of Response: 12/12/2025
View Response: 10859.pdf
Freedom of Information Request Reference: 10858
Date Received: 18/11/2025
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available? 1.1 Acalabrutinib (Calquence) 1.2 Ibrutinib (Imbruvica) 1.3 Pirtobrutinib (Jaypirca) 1.4 Venetoclax (Venclyxto) 1.5 Zanubrutinib (Brukinsa) 1.6 Rituximab 1.7 Obinutuzumab (Gazyvaro) Q2. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available? 2.1 Acalabrutinib (Calquence) 2.2 Ibrutinib (Imbruvica) 2.3 Pirtobrutinib (Jaypirca) 2.4 Venetoclax (Venclyxto) 2.5 Zanubrutinib (Brukinsa) 2.6 Obinutuzumab (Gazyvaro) 2.7 Rituximab 2.8 Bendamustine 2.9 Chlorambucil 2.10 Fludarabine 2.11 Cyclophosphamide Q3. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available? 3.1 Ibrutinib + venetoclax 3.2 Obinutuzumab + venetoclax 3.3 Zanubrutinib monotherapy / maintenance 3.4 Ibrutinib monotherapy / maintenance 3.5 Venetoclax monotherapy 3.6 Venetoclax + rituximab 3.7 Rituximab monotherapy 3.8 Ibrutinib + Bendamustine + Rituximab Q4. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available? 4.1 Acalabrutinib 4.2 Ibrutinib 4.3 Zanubrutinib 4.4 Ibrutinib + R-CHOP / R-DHAP 4.5 Pirtobrutinib Q5. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available? 5.1 Azacitidine 5.2 Cytarabine 5.3 Venetoclax (Venclyxto) Q6. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available? 6.1 Venetoclax + Azacitidine (with or without posaconazole) 6.2 Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C) Q7. How many patients with Multiple Myeloma were treated with the following medicines in combination, in the 3 months between the start of July 2025 and end of September 2025, or latest 3-month period available? 7.1 Daratumumab + Bortezomib + Dexamethasone [DVd] 7.2 Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd] 7.3 Daratumumab + Lenalidomide + Dexamethasone [DRD] 7.4 Lenalidomide + Dexamethasone [Rd] 7.5 Lenalidomide (maintenance monotherapy) 7.6 Carfilzomib + Dexamethasone [Kd] 7.7 Belantamab mafodotin (monotherapy) 7.8 Belantamab mafodotin + Bortezomib + Dexamethasone [BVd] 7.9 Daratumumab (monotherapy) 7.10 Isatuximab + Bortezomib + Lenalidomide + Dexamethasone [IsaVRd] 7.11 Isatuximab + Pomalidomide + Dexamethasone [IsaPd]
Date of Response: 15/12/2025
View Response: 10858.pdf
Freedom of Information Request Reference: 10857
Date Received: 18/11/2025
Summary:
Under the Freedom of Information Act 2000, I hereby request the following information for the period 01 January 2024 – 31 December 2024 (and, if available, for the preceding years 2023, 2022): 1. The total number of ADAMTS13 activity assays performed by your laboratory in the stated period(s). 2. If applicable, how many of these tests were performed in‑house vs sent to an external/reference laboratory. If sent away, please name the receiving laboratory(ies). 3. The number of unique patients who had at least one ADAMTS13 test in the period(s). 4. If you collect them, separate numbers for ADAMTS13 inhibitor/antibody assays. 5. The diagnostic assays/tools that were used to perform the ADAMTS13 activity and/or inhibitor assays. (e.g. Werfen acustar, technoclone ceveron, in-house FRET, ELISA)
Date of Response: 12/12/2025
View Response: 10857.pdf
Freedom of Information Request Reference: 10856
Date Received: 18/11/2025
Summary:
The number of adults who have presented at hospital for help removing foreign objects from their rectal or vaginal passage, from November to January (November, December, January), each year since 2015. A list of the items that have been retrieved each year during this period (November, December, and January, 2015-2025).
Date of Response: 11/12/2025
View Response: 10856.pdf
Freedom of Information Request Reference: 10854
Date Received: 18/11/2025
Summary:
This is a formal non medical Freedom of Information Request in accordance with the legislation relating to access to part of the Royal Edinburgh Hospital estate. “ Please supply the information regarding who owns the short final access road and turning area in front of the Royal Edinburgh Building within the Royal Edinburgh Hospital boundary Morningside, Edinburgh”
Date of Response: 11/12/2025
View Response: 10854.pdf
Freedom of Information Request Reference: 10853
Date Received: 18/11/2025
Summary:
The total number of unique patients who attended an Accident and Emergency (A&E) department within your health board during the 2024-2025 financial year?
Date of Response: 12/12/2025
View Response: 10853.pdf
Freedom of Information Request Reference: 10850
Date Received: 17/11/2025
Summary:
For each of the last five calendar years (or the last three years if five is not possible), please provide: The number of patients treated at your hospital for reconstructive or corrective eye surgery due to complications from eye-colour changing procedures carried out abroad. If possible and it does not exceed the cost: Of those cases, please specify how many were linked to: Iris implant surgery, Keratopigmentation, laser depigmentation, or any other cosmetic procedure intended to alter eye colour.
Date of Response: 16/12/2025
View Response: 10850.pdf
Freedom of Information Request Reference: 10849
Date Received: 17/11/2025
Summary:
1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel (Jevtana or generic cabazitaxel) 1.4 Darolutamide (Nubeqa) 1.5 Enzalutamide (Xtandi) 1.6 Talazoparib (Talzenna) 1.7 Docetaxel 1.8 Relugolix (Orgovyx, Ryeqo) 1.9 Olaparib (Lynparza) 2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer 2.4 Relugolix (Orgovyx) for prostate cancer 3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 3.1 Abiraterone (Zytiga or generic abiraterone) 3.2 Apalutamide (Erleada) 3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 3.4 Darolutamide (Nubeqa) 3.5 Enzalutamide (Xtandi) 4. How many patients were treated with the following combinations in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle. Name of medicine 4.1 Darolutamide (Nubeqa) + Docetaxel 4.2 Darolutamide (Nubeqa) 4.3 Olaparib (Lynparza) + Abiraterone 5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 5.1 Abiraterone 5.2 Enzalutamide 6. How many patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal cancer were treated with platinum chemotherapy between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available? 7. How many patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal cancer received maintenance therapy between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available? 8. How many patients were treated with olaparib (Lynparza) for the following types of cancer between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available? ICD-10 codes C50* or D05 C56* or C57* or C79.6 or C79.8 or C48.1 or C48.2 C61* 9. How many patients were treated with olaparib (Lynparza) for the following indications and BlueTeq CDF codes between 1st Jul 2025 and 30th Sep 2025, or latest 3-month period for which data is available?
Date of Response: 12/12/2025
View Response: 10849.pdf
Freedom of Information Request Reference: 10848
Date Received: 14/11/2025
Summary:
Q1. Within your Trust, how many patients in total were admitted as inpatients between July – October 2025 with a primary cause of admission being a chronic obstructive pulmonary disease (COPD) exacerbation (ICD-10: J44.1)? Q2. Of the patients admitted with a primary COPD exacerbation (ICD-10: J44.1) identified in Q1, how many were already prescribed a closed triple therapy* at the point of admission? *Closed triple therapy = Trelegy, Trixeo, or Trimbow (any formulation) *“Already prescribed” means the therapy was documented as active on admission, either from hospital records or patient-reported history. Q3. How many patients in total were prescribed Trixeo for COPD (ICD-10: J44.1) between July – October 2025? How many of these were new to Trixeo*? *New to Trixeo = Patient not prescribed Trixeo in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trixeo—whether prescribed in hospital or community settings—at the point of admission. Q4. How many patients in total were prescribed Trimbow MDI (for COPD [ICD-10: J44.1]) between July – October 2025? · How many of these were new to Trimbow MDI*? · Of the new Trimbow MDI patients*, what was the split between: · Trimbow MDI 87/5/9 · Trimbow MDI 172/5/9 *New to Trimbow MDI = Patient not prescribed Trimbow MDI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow MDI—whether prescribed in hospital or community settings—at the point of admission. Q5. How many patients in total were prescribed Trelegy for COPD (ICD-10: J44.1) between July – October 2025? How many of these were new to Trelegy*? *New to Trelegy = Patient not prescribed Trelegy in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trelegy—whether prescribed in hospital or community settings—at the point of admission. Q6. How many patients in total were prescribed Trimbow DPI (for COPD [ICD-10: J44.1]) between July – October 2025? How many of these were new to Trimbow DPI*? *New to Trimbow DPI = Patient not prescribed Trimbow DPI in your hospital (inpatient or outpatient) in the past 12 months (Nov 2024 – Oct 2025), and not currently prescribed Trimbow DPI—whether prescribed in hospital or community settings—at the point of admission.
Date of Response: 09/12/2025
View Response: 10848.pdf
Freedom of Information Request Reference: 10847
Date Received: 14/11/2025
Summary:
For your organisation, can you please provide me a list of: Employee/Staff Networks recognised by your organisation. Details of any funding provided to that network by your organisation or external source e.g. charity and how that funding has been spent for the past three financial years, broken down by year where possible. Details of any administrative support provided to the organisation, including a breakdown of time/banding of employee providing said support. Any facility/protected time that the network lead (chair, vice chair etc) gets as part of their role. Details of any executive/senior management responsibility for the network. A copy of the terms of reference/memorandum of understanding/network agreement for each network recognised by your organisation, where this document exists.
Date of Response: 11/12/2025
View Response: 10847.pdf
Freedom of Information Request Reference: 10846
Date Received: 14/11/2025
Summary:
I am writing to ask under the provisions of the Freedom of Information (Scotland) Act 2002 that the Board provides me with the following information on employees: • The average length of service of all current employees expressed as a single figure in years and months • The average length of service of all employees and allocated to 10 year groupings, i.e. up to 10 years, between 10 and 20 years, between 20 and 30 years, between 30 and 40 years, and between 40 and 50 years • The average length of service of all employees according to the protected characteristic of sex, with an average for all men and another for all women [sex as defined by the Supreme Court in April 2025 as biological and binary] • The average length of service of all employees according to the protected characteristic of sex, with an average for all men and an average for all women, and allocated to 10 year groupings, i.e. up to 10 years, between 10 and 20 years, between 20 and 30 years, between 30 and 40 years, and between 40 and 50 years • The average length of service of all employees according to the protected characteristic of sex at the point they leave employment with the Board, with an average for all employees, an average for all men and another average for all women • The average length of service of all employees according to the protected characteristic of ethnicity using these sub-groupings [BME - Mixed or Multiple Ethnic Group, Asian Pakistani, Asian Indian, Asian Bangladeshi, Asian Chinese, Asian Other, African, African Other, Caribbean, Black, Caribbean or Black Other, Arab and Other Ethnic Group - White Minority - White Irish, White Gypsy/Traveller, White Polish and White Other - All Other White British - White English, White Northern Irish, White Welsh and White Other British] • The average length of service of all employees according to the protected characteristic of ethnicity using these 3 sub-groups [BME - Mixed or Multiple Ethnic Group, Asian Pakistani, Asian Indian, Asian Bangladeshi, Asian Chinese, Asian Other, African, African Other, Caribbean, Black, Caribbean or Black Other, Arab and Other Ethnic Group - White Minority - White Irish, White Gypsy/Traveller, White Polish and White Other - All Other White British - White English, White Northern Irish, White Welsh and White Other British], and allocated to 10 year groupings, i.e. up to 10 years, between 10 and 20 years, between 20 and 30 years, between 30 and 40 years, and between 40 and 50 years • The average length of service of all employees according to the protected characteristic of ethnicity at the point they leave employment with the Board, with an average for all employees and average for each of the above three sub-groups • The average length of service of all employees according to the protected characteristic of disability, with an average for all disabled people and another for all other employees not identifying as disabled • The average length of service of all employees according to the protected characteristic of disability, with an average for all disabled people and an average for all employees not identifying as disabled, and allocated to 10 year groupings, i.e. up to 10 years, between 10 and 20 years, between 20 and 30 years, between 30 and 40 years, and between 40 and 50 years • The average length of service of all employees according to the protected characteristic of disability at the point they leave employment with the Board, with an average for all employees, an average for all disabled people and an average for all employees not identifying as disabled.
Date of Response: 11/12/2025
View Response: 10846.pdf
Freedom of Information Request Reference: 10845
Date Received: 14/11/2025
Summary:
Please provide information on whether any doctors who have transferred from a General Medical Services (GMS) practice into employment within NHS Lothian, and who have been employed by NHS Lothian for less than 12 months at the start of their maternity leave, have been awarded or received occupational maternity pay. If available, please include: • The number of such cases, if any. • Any policies, procedures, or guidance that set out the criteria for awarding occupational maternity pay in these circumstances.
Date of Response: 19/12/2025
View Response: 10845.pdf
Freedom of Information Request Reference: 10844
Date Received: 14/11/2025
Summary:
Question One How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments: Atezolizumab (Tecentriq) Avelumab (Bavencio) Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Nivolumab (Opdivo) Cisplatin with Gemcitabine + Avelumab (Bavencio) Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) Nivolumab (Opdivo) Pembrolizumab (Keytruda) Other active systemic anti-cancer therapy Palliative care only Erdafitinib Question Two How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies: Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Avelumab (Bavencio) Question Three Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Date of Response: 09/12/2025
View Response: 10844.pdf
Freedom of Information Request Reference: 10843
Date Received: 13/11/2025
Summary:
Please provide responses to the following for the most recent full financial year (April 2024 – March 2025). 1. Who is the person responsible for commissioning pulmonary rehabilitation services within your organisation? Please include their name, job title, and contact email if available. 2. Which provider organisations are currently delivering pulmonary rehabilitation services under contract with your organisation? 3. How many people were referred to pulmonary rehabilitation during the most recent full financial year? 4. Of those referred, how many completed a full pulmonary rehabilitation programme during the same period? 5. For which primary conditions or diagnoses do you refer patients to pulmonary rehabilitation? 6. How many individuals are currently on a waiting list for pulmonary rehabilitation, and what is the average waiting time if available? 7. What types or formats of pulmonary rehabilitation are currently offered (for example, face-to-face, home-based, or digital such as MyCOPD)? 8. What outcome measures are used to evaluate pulmonary rehabilitation services (e.g. CAT score, six-minute walk test)?
Date of Response: 15/12/2025
View Response: 10843.pdf
Freedom of Information Request Reference: 10842
Date Received: 13/11/2025
Summary:
1. In each year since 2020-21, including the current year to date, how many employees at this public body have been suspended with full pay? Where an employee’s suspension covers multiple financial years, please only include the year where they were initially suspended. 2. In relation to Q1, what is the respective salary of these employees? 3. Please provide as much detail as possible on why these employees were suspended. E.g. Disciplinary issues, poor quality of work etc.
Date of Response: 15/12/2025
View Response: 10842.pdf
Freedom of Information Request Reference: 10841
Date Received: 13/11/2025
Summary:
1. Cardiac Catheterisation Laboratories (Cath labs) and their utilisation What is the number of cath labs currently in operation within your organisation and the sites at which they are located. In how many of these cath labs do you perform catheter-based valve interventions? How many days per week are catheter-based valve interventions performed in each of these cath labs? Any available data on utilisation of these facilities (e.g. number of sessions scheduled per week, or average percentage utilisation). 2. Cardiac Theatres (used for cardiac surgery) - What is the number and location of cardiac theatres in operation. What is the total number of heart valve repair or replacement procedures (e.g. TAVI, TEER, sAVR or Bentall procedures) performed in both cath labs and cardiac theatres during the most recent full year for which you hold data. 3. Planning How is the provision or planning of the following procedures managed within your jurisdiction for: - Transcatheter Aortic Valve Implantation (TAVI) - Transcatheter Edge-to-Edge Repair (TEER) Are there any current or planned investments in cardiac catheterisation or cardiac surgical capacity (including infrastructure or workforce)? What is the size of the population which is covered by your cardiac service provision?
Date of Response: 11/12/2025
View Response: 10841.pdf
Freedom of Information Request Reference: 10840
Date Received: 13/11/2025
Summary:
Did NHS Lothian implement the British Transplantation Society COVID 19 Guidelines (Guidance on the management of transplant recipients diagnosed with or suspected of having COVID 19) first published in the spring (24th April) of 2020? If so, what date was the guidance implemented?
Date of Response: 11/12/2025
View Response: 10840.pdf
Freedom of Information Request Reference: 10839
Date Received: 13/11/2025
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available? Name of medicine 1.1 Abemaciclib (Verzenios) 1.2 Alpelisib (Piqray) 1.3 Elacestrant (Orserdu) 1.4 Fulvestrant (fulvestrant or Faslodex) 1.5 Inavolisib (Inaqovi) 1.6 Palbociclib (Ibrance) 1.7 Ribociclib (Kisqali) 1.8 Capivasertib (Truqap) 1.9 Talazoparib (Talzenna) 1.10 Olaparib (Lynparza) Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available? Name of combination or monotherapy 2.1 Abemaciclib (Verzenios) 2.2 Ribociclib (Kisqali) 2.3 Olaparib (Lynparza) Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available? Name of combination or monotherapy 3.1 Abemaciclib (Verzenios) 3.2 Ribociclib (Kisqali) Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available? Name of combination or monotherapy 4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) 4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) 4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of July 2025 and the end of September 2025? Type of breast cancer 5.1 Olaparib - All types of breast cancer 5.2 Olaparib - Locally advanced or metastatic breast cancer 5.3 Talazoparib – All types of breast cancer Q6. How many patients were treated in total with the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 6.1 Pertuzumab (Perjeta) 6.2 Pertuzumab with Trastuzumab (Phesgo) 6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 6.4 Trastuzumab Deruxtecan (EnHertu) 6.5 Trastuzumab Emtansine (Kadcyla) 6.6 Tucatinib (Tukysa) 6.7 Neratinib (Nerlynx) Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Name of medicine 7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 7.2 Trastuzumab Deruxtecan (EnHertu) Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available? Products 8.1 Pertuzumab (Perjeta) 8.2 Pertuzumab with Trastuzumab (Phesgo) 8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) 8.4 Trastuzumab Emtansine (Kadcyla) Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available? Products 9.1 Pertuzumab (Perjeta) 9.2 Pertuzumab with Trastuzumab (Phesgo) 9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 9.4 Trastuzumab Emtansine (Kadcyla)   Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available? Treatment intent 10.1 HER2+ve Breast Cancer 10.2 HER2-low Breast Cancer Q11. How many patients were treated for the following indications for metastatic HER2+ve breast cancer by product, in the 3 months between 1st July 2025 and 30th September 2025, or latest 3-months for which data are available? Name of medicine Line of Therapy (indication) 11.1 Trastuzumab Deruxtecan (Enhertu) Following one or more prior anti-HER2-based regimens 11.2 Trastuzumab Deruxtecan (Enhertu) Following one prior anti HER2-based regimen 11.3 Trastuzumab Emtansine (Kadcyla) Following one or more prior anti-HER2-based regimens 11.4 Trastuzumab Emtansine (Kadcyla) Following one prior anti HER2-based regimen 11.5 Trastuzumab Following one or more prior anti-HER2-based regimens 11.6 Trastuzumab Following one prior anti HER2-based regimen
Date of Response: 05/12/2025
View Response: 10839.pdf
Freedom of Information Request Reference: 10838
Date Received: 12/11/2025
Summary:
Contract 1 – Wide Area Network (WAN) Services (Including HSCN) 1. WAN Provider(s) Please confirm the main supplier(s) for your WAN services. If this information is not available, please explain why. 2. Contract Expiry Date Please provide the expiry date for each WAN contract (DD/MM/YYYY or MM/YYYY acceptable). If rolling, please state the terms. 3. Contract Description Please provide a brief summary of the scope of each WAN contract. 4. Number of Sites Covered Please indicate the number of sites supported by the WAN. An approximation is acceptable. 5. Annual Average Spend What is the annual average spend for WAN services? Please break this down by provider if more than one. 6. Procurement Route Please provide details of how each WAN contract was procured. If a framework was used, please include the framework name and reference number. ________________________________________ Internal Contact Please provide the full contact details for the person(s) responsible for each of the above contracts, including: • Full name • Job title • Direct phone number • Email address
Date of Response: 05/12/2025
View Response: 10838.pdf
Freedom of Information Request Reference: 10837
Date Received: 12/11/2025
Summary:
How many SAER ( significant adverse event reviews) reviews took place within Edinburgh Royal Infirmary in the last 12 months? Of these SAER's how many resulted in a death? How many SAERs took place in The Royal Edinburgh hospital in the same 12 months and of these how many resulted in a patient death.?
Date of Response: 16/12/2025
View Response: 10837.pdf
Freedom of Information Request Reference: 10836
Date Received: 12/11/2025
Summary:
The information I request is: for each of your surgeons who have performed cataract operations during the past three years, for each of the past three years, the number of cataract operations performed, percent operations with posterior capsule rupture and percent operations with vision loss.
Date of Response: 11/12/2025
View Response: 10836.pdf
Freedom of Information Request Reference: 10835
Date Received: 12/11/2025
Summary:
Please can you confirm the below: • Spend on Insourcing from August 2025-end of October 2025, broken down by each specialty and subspecialty, and the insourcing company that was used, e.g. cardiology £1000- echo cardiogram £1000- company x £1000 • The budget for each specialty for insourcing • Confirm the contract start and end date for each specialty • What frameworks were used for each specialty and was there direct awards and if so, who was they awarded to and what specialty • What was the service, e.g. theatres, outpatient, or diagnostic
Date of Response: 11/12/2025
View Response: 10835.pdf
Freedom of Information Request Reference: 10834
Date Received: 12/11/2025
Summary:
I am unhappy with the Board’s response for a number of reasons and would invite the Board to review the response and attempt to actually answer the questions put. In the Board’s response to the first question, the Board said: Three of the strategic priorities demonstrate how NHS Lothian is giving due regard to the need to foster good relations between people who share the protected characteristic of gender reassignment and those who do not are ………. This is quite simply wrong. I asked for: some or all of the distinct actions and steps aimed at ‘fostering good relations’ between the two cohorts [defined in the preceding paragraph as being between people with the protected characteristic of ‘gender reassignment’ and people who share the protected characteristic of ‘sex’ and who are women]. This renders the Board response as both wrong and irrelevant, and attempting to substitute strategic priorities for ‘distinct actions and steps’. Given this is fundamental to the issues on which information has been asked, I would invite the Board to learn from the mistakes and review and revise the answers to provide distinct actions and steps aimed at ‘fostering good relations’ between the two cohorts [defined as being between people with the protected characteristic of ‘gender reassignment’ and people who share the protected characteristic of ‘sex’ and who are women], both pre- and post-Supreme Court judgement. In addition, I had asked for information on: could you also please let me know what benchmarking, data gathering and other systemic changes were put in place to track the actual impact of ‘fostering good relations’ actions between the two cohorts and what measurable outcomes these showed or produced, pre-Supreme Court judgement ? The Board’s answer was: In January 2025, NHS Lothian started the first annual equality and human rights staff survey. This survey aims to identify staff views about the extent to which NHS Lothian is making progress towards achieving the equality and human rights strategic priorities and staff experiences of discrimination, harassment, bullying and behaviour that is described as microaggressions This is a broad brushstroke answer to a very specific question and will not necessarily provide relevant and/or accurate data on relations between the two cohorts the subject of my original request. It is also only a partial answer as it deals with staff views. The views and experiences of both cohorts as service users appear to have been overlooked/ignored by the Board. In the overall review of the Board’s response I would invite the Board to set out answers which include answers containing data relevant to service users from the two cohorts. Overall, the Board’s response falls considerably short of what was in fact asked and does beg the question of whether those responsible for compiling the response actually understood what was being asked for or indeed understood the contest of the request.
Date of Response: 11/12/2025
View Response: 10834.pdf
Freedom of Information Request Reference: 10833
Date Received: 11/11/2025
Summary:
The questions refer to the time period of 2024-2025. Can you please provide answers to the following questions for your health board area. Workforce 1. The following sub-questions refer to qualified/registered audiologists in your department (please include audiologists and clinical scientists that provide audiological services): a) How many audiologists do you have in headcount? b) How many audiologists do you have in full time equivalents (FTE)? c) How many FTE job vacancies do you have for qualified audiologists/registered audiologists? Services 2. What % of patients referred to adult audiology services for a hearing assessment are referred a) from ENT and b) directly from their GP? 3. How many adult hearing assessments were performed in 2024/25? 4. How many adults were fitted with hearing aids in 2024/25? And how many were new patients? 5. What is the average time a patient waits to receive their hearing aid(s) after referral from their GP? 6. What is the local bilateral fitting rate? (please just state the percentage – i.e. an explanation is not required). 7. After fitting a hearing aid, what are the average wait times for a follow up appointment? 8. How often are patients offered a reassessment? (i.e., how many years after they are fitted are patients recalled for a routine hearing assessment to check their hearing and whether hearing aids need reviewing/replacing) 9. How are follow up care and reassessments delivered e.g., structured and requested from the audiology department or left to patient-initiated follow-up (PIFU)? 10. Please list all locations that provide adult hearing services in your health board area and what services are provided at each location.
Date of Response: 09/12/2025
View Response: 10833.pdf
Freedom of Information Request Reference: 10832
Date Received: 11/11/2025
Summary:
1. Any programme budgeting or internal costing that separately identified endometriosis (ICD - 10 N80) 2. Annual spend on endometriosis diagnosis/treatment (surgery, imaging, outpatient clinics, specialist centre budgets) for the last 5-7 years.
Date of Response: 05/12/2025
View Response: 10832.pdf
Freedom of Information Request Reference: 10831
Date Received: 11/11/2025
Summary:
Q1. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: • Dostarlimab (Jemperli) • Dostarlimab (Jemperli) AND Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Pembrolizumab (Keytruda) monotherapy • Lenvatinib + Pembrolizumab (Lenvima +Keytruda)  • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other Chemotherapy • Durvalumab with platinum-based chemotherapy • Pembrolizumab with platinum-based chemotherapy Q2. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: • Dostarlimab (Jemperli) AND Chemotherapy • Durvalumab with platinum-based chemotherapy • Pembrolizumab with platinum-based chemotherapy • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other chemotherapy Q3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.
Date of Response: 10/12/2025
View Response: 10831.pdf
Freedom of Information Request Reference: 10830
Date Received: 24/10/2025
Summary:
During our conversations with NHS Facilities we have been advised they do not hold vital information that has led to problems in agreeing our shared understanding and being able to move forward. I attach a NHS document from November 2006 detailing the current arrangement and invoices relating to this. Specifically the long standing reimbursement process set up by NHS Lothian. I would be grateful if you can confirm if you also hold this information.
Date of Response: 19/12/2025
View Response: 10830.pdf
Freedom of Information Request Reference: 10829
Date Received: 11/11/2025
Summary:
In the week beginning 3 November, how much did the NHS spend on food for patients? In the week beginning 3 November 2025, what was the nutritional value of each standard meal provided to patients? In the week beginning 3 November 2025, what was the calorie content of each standard meal provided to patients? In the week beginning 3 November 2025, how many standard patient meals contained ultra processed food?
Date of Response: 10/12/2025
View Response: 10829.pdf
Freedom of Information Request Reference: 10828
Date Received: 10/11/2025
Summary:
Please provide: 1. The number of adult inpatients (aged 18+) in NHS Lothian hospitals in each of the last three financial years (2022/23, 2023/24, and year-to-date 2025) who were recorded as being delayed in hospital discharge due to: o a) Absence of a registered Power of Attorney; and/or o b) A pending or required guardianship order. 2. The average and longest length of delay (in days) for patients where (a) or (b) above was a contributing factor. 3. Any available internal data or assessments regarding the impact of capacity-related discharge delays (e.g., cost to NHS, bed occupancy, or patient outcomes). 4. If available, any policy documents, guidance, or reports produced by NHS Lothian or the relevant Health and Social Care Partnership relating to capacity, guardianship, or Power of Attorney and hospital discharge.
Date of Response: 09/12/2025
View Response: 10828.pdf
Freedom of Information Request Reference: 10826
Date Received: 11/11/2025
Summary:
I was looking for retention data such as but not limited to: • The average length of service [in years and months] of the current workforce • The average length of service of those leaving government employment • The average length of service of each cohort [men and women in the protected characteristic of sex for example] within each of the protected characteristics • The average sickness absence rates alongside the average length of service of each cohort within each of the protected characteristics
Date of Response: 05/12/2025
View Response: 10826.pdf
Freedom of Information Request Reference: 10825
Date Received: 11/11/2025
Summary:
The number individuals diagnosed with mesothelioma in NHS Lothian, by hospital, for the period 2020 to date, broken down by year, if possible.
Date of Response: 11/12/2025
View Response: 10825.pdf
Freedom of Information Request Reference: 10824
Date Received: 11/11/2025
Summary:
1. What proportion of men waiting for bladder outlet surgery were catheterised prior to surgery, in the quarter ending 30th June 2025? 2. What proportion of men undergoing bladder outlet surgery had a urinary catheter when they were admitted for surgery, in the quarter ending June 2025? 3. If a man presents with urinary retention and is catheterised or taught to self-catheterise what is the average time to surgery for these men? 4. What was the average waiting time for men with lower urinary tract symptoms from referral to specialist Urology services to treatment decision, in the quarter ending 30th June 2025? 5. What was the average waiting time for men with lower urinary tract symptoms from treatment decision to surgery, in the quarter ending June 2025?
Date of Response: 05/12/2025
View Response: 10824.pdf
Freedom of Information Request Reference: 10823
Date Received: 11/11/2025
Summary:
1. How many beds in use in hospitals does your Health Board have ? 2. How many beds not in use in Hospitals does your Health Board have? 3 How many hospital beds are in use for Thrombosis related conditions.? 4 How much on average does it cost per day (24 hours)to care for Thrombosis related conditions?
Date of Response: 05/12/2025
View Response: 10823.pdf
Freedom of Information Request Reference: 10822
Date Received: 11/11/2025
Summary:
Please provide the following information for the period 1 January 2015 to the present: 1. The total number of formal complaints, Datix reports, or clinical-governance investigations that named or involved Dr ~~~~~~. 2. For each, whether the outcome was upheld, partially upheld, or dismissed. 3. The broad subject category of each complaint (for example, communication, treatment delay, informed consent, clinical decision-making, or patient-family relations). 4. Any actions, recommendations, or retraining recorded as outcomes of those investigations. 5. Any external reviews, audits, or service evaluations of paediatric oncology in which Dr ~~~~~~ clinical practice or decision-making was specifically discussed or reviewed.
Date of Response: 08/12/2025
View Response: 10822.pdf
Freedom of Information Request Reference: 10821
Date Received: 11/11/2025
Summary:
I must formally advise that the statutory deadline for a substantive response, which your team confirmed was 10 November 2025, has now passed without the information being provided.
Date of Response: 10/12/2025
View Response: 10821.pdf
Freedom of Information Request Reference: 10820
Date Received: 10/11/2025
Summary:
I note that the response you have provided refers to a referral from a GP practice on 12 January 2023 and 16 January 2023. Please can you confirm if the quoted average wait time of around 9 calendar days would have differed in the event an urgent referral was made by the referring GP practice on these two dates?
Date of Response: 11/12/2025
View Response: 10820.pdf
Freedom of Information Request Reference: 10819
Date Received: 10/11/2025
Summary:
Q1. Please provide the total number of patients treated in the last 6 months for: •Polycythaemia Vera (ICD10 code D45) •Myelofibrosis (ICD10 code D47.4) •Myelofibrosis (ICD10 code D47.4) patients aged 65 and older Q2. How many patients were treated in the past 6 months (for any disease) with: •Ruxolitinib •Fedratinib •Momelotinib Q3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases? •Myelofibrosis (ICD10 code D47.4) •Polycythaemia Vera (ICD10 code D45) •Other/Unknown Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? •Of these patients, how many were treated in the past 6 months with Hydroxycarbamide? •Of these patients, how many were treated in the past 6 months with Interferon therapy? •Of these patients, how many have received no active treatment in the past 6 months?
Date of Response: 04/12/2025
View Response: 10819.pdf
Freedom of Information Request Reference: 10818
Date Received: 10/11/2025
Summary:
1. Please provide Hemophilia A patient numbers broken down by: age, disease severity and treatment regimen (PPx denotes use for prophylaxis and OD denotes use on demand). I have proposed a format below to capture the relevant information. If data is not available by age breakdown, then please provide aggregated total in the yellow highlighted column: July through September 2025 Age Brand name (scientific) 0-12 years 13+ Mild Moderate Severe Mild Moderate Severe PPx OD PPx OD PPx OD PPx OD PPx OD PPx OD Hemlibra (emicizumab) Altuvoct (giroctocogene fitelparvovec) Esperoct (turoctocog alfa pegol) Elocta (efmoroctocog alfa) Advate (octocog alfa) Kovaltry (octocog alfa) Iblias (octocog alfa) Refacto AF (moroctocog alfa) Xyntha (moroctocog alfa) NovoEight (turoctocog alfa) Nuwiq (simoctocog alfa) Vihuma (simoctocog alfa) Inhibitor patients 2. For Hemlibra-treated Hemophilia A Inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3’25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total: Age group (Hemophilia A inhibitor patients) Once weekly Every 2 weeks Every 4 weeks 0-12 years 13+ years Total Non-inhibitor patients 3. For Hemlibra-treated Hemophilia A non-inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3’25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total: Age group (Hemophilia A non-inhibitor patients) Once weekly Every 2 weeks Every 4 weeks 0-12 years 13+ years Total
Date of Response: 05/12/2025
View Response: 10818.pdf
Freedom of Information Request Reference: 10817
Date Received: 05/11/2025
Summary:
I have read the reply but I think I am entitled to the information as it relates to me as the driver of the vehicle in question. According to the Telematics Guidance Document for users of NHLS Vehicles, Traffilog stores all recorded information from the initial go-live date. All users have the right to request, via their line manager, a copy of all information on their own stored data. Where stored data is not relevant to a member of staff, it will not be shared in any circumstances. Information recorded and stored by the telematics systems will be available and published in an anonymised format should NHSL receive a Freedom of Information request. It looks to me that I am entitled to the information I have requested as I was the driver of said vehicle. I look forward to your reply.
Date of Response: 28/11/2025
View Response: 10817.pdf
Freedom of Information Request Reference: 10816
Date Received: 06/11/2025
Summary:
Please provide the following information relating to your organisation’s use of temporary agency staffing. 1. Neutral Vend / Master Vend Do you use a Neutral Vend (NV) or Master Vend (MV) supplier for the following staff groups? If yes, please complete: Staff Group Supplier Name Contract Expiry Date Medical Allied Health Professionals (AHPs) Non-Medical, Non-Clinical (NMNC) Nursing 2. Direct Engagement (DE) Do you use a Direct Engagement supplier for any of the following staff groups? If yes, please complete: Staff Group DE Provider Contract Expiry Date % of Agency Spend via DE Medical Allied Health Professionals (AHPs) Non-Medical, Non-Clinical (NMNC) 3. Agency Spend (Most Recent Financial Year) Please provide total agency spend (worker pay & agency commission only): Staff Group Total Spend (£) Medical Allied Health Professionals (AHPs) Non-Medical, Non-Clinical (NMNC) Nursing 4. Agency Hours (Most Recent Financial Year) If you can access this information, please provide the total number of agency worker hours: Staff Group Total Hours Worked Medical Allied Health Professionals (AHPs) Non-Medical, Non-Clinical (NMNC) Nursing 5. Contract Management For any Neutral Vend, Master Vend, or Direct Engagement contracts in place, please provide: • Name of lead contact/responsible officer: • Job title: • Email address:
Date of Response: 28/11/2025
View Response: 10816.pdf
Freedom of Information Request Reference: 10815
Date Received: 10/11/2025
Summary:
Can I request, broken down by the calendar years 2019, 2020, 2021, 2022, 2023, 2024 and 2025 (most recent data): 1. How many midwifery shifts have gone unfilled after being put out for agency or bank cover, broken down by position. 2. How many obstetrics shifts have gone unfilled after being put out for locum cover, broken down by position (e.g. consultant, resident doctor).
Date of Response: 05/12/2025
View Response: 10815.pdf
Freedom of Information Request Reference: 10814
Date Received: 10/11/2025
Summary:
1. What was the percentage mark-up on the sale of sugar-sweetened beverages, confectionery, cakes, biscuits and similar items that were sold by your health board to patients, staff, and the public? 2. What was the profit made by your health board as a result of selling those items defined above?
Date of Response: 05/12/2025
View Response: 10814.pdf
Freedom of Information Request Reference: 10813
Date Received: 07/11/2025
Summary:
Request in relation to CCTV footage.
Date of Response: 07/11/2025
View Response: 10813.pdf
Freedom of Information Request Reference: 10812
Date Received: 07/11/2025
Summary:
How many formal complaints of bullying were made by midwives, consultant obstetricians, maternity care assistants, or other staff members working in the labour ward at the Royal Infirmary of Edinburgh in each calendar year from 2019 to 2025 (to date). How many formal complaints of bullying were made by other NHS staff departments at the Royal Infirmary of Edinburgh from 2019 to 2025 (to date). For example, break it down by A&E, paediatrics, etc.
Date of Response: 08/12/2025
View Response: 10812.pdf
Freedom of Information Request Reference: 10811
Date Received: 07/11/2025
Summary:
Please provide details of roles (role title and reporting structure), including information relating to Agenda For Change bandings as well as copies of any job descriptions. Please be advised I am not looking for personal details relating to post holders, such as the names of any individual staff members. Could you please confirm, for each post, the source of funding e.g. funded by internal budgets (and which budget e.g. medical), funded by Scottish Government etc.
Date of Response: 05/12/2025
View Response: 10811.pdf
Freedom of Information Request Reference: 10810
Date Received: 06/11/2025
Summary:
1. Temporary Staffing Agency Spend (1st June 2025 – 31st October 2025) • The total spend on agency Mental Health Nurses (including both inpatient and community roles such as CPNs), broken down by Band (2, 3, 5, 6, 7) excluding VAT: Band Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 • The total hours filled by agency Mental Health Nurses (including both inpatient and community roles such as CPNs) Band Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 2. Agency Supplier Information For each agency currently supplying Mental Health Nurses (Bands 2, 3, 5, 6, 7), please provide: a. Agency Name b. Agreed Charge Rates (total hourly cost to the Trust) for each Band c. Total Hours Supplied by each agency, broken down by Band, for the period 1st June 2025 – 31st October 2025. 3. Temporary Staffing Management Contacts • The department or team responsible for managing agency Mental Health Nurses (e.g., Workforce Planning, HR, Medical Staffing) • If available, a general contact phone number &/or email for workforce enquiries • If available, a contact name for Temporary staffing manager/lead and email
Date of Response: 11/12/2025
View Response: 10810.pdf
Freedom of Information Request Reference: 10809
Date Received: 06/11/2025
Summary:
In the period 1st August 2025 to 31st October 2025 please provide a breakdown of: • Total trust spend with framework agencies for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name  In the period 1st August 2025 to 31st October 2025 please provide a breakdown of: • Total trust spend with off-framework agencies for locums doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name  In the period 1st August 2025 to 31st October 2025 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum doctors for the period 1st August 2025 to 31st October 2025 Please confirm the name of the framework used for the supply of locum doctors in your trust.
Date of Response: 04/12/2025
View Response: 10809.pdf
Freedom of Information Request Reference: 10808
Date Received: 06/11/2025
Summary:
I am requesting the following from the Financial Year 2024/25: 1. The a) number of individuals receiving prescriptions, b) the number of prescriptions issued and c) the total cost of the prescriptions issued, for food products. 2. The a) number of individuals receiving prescriptions, b) the number of prescriptions issued and c) the total cost of the prescriptions issued, for weight loss drugs (including pills and injections).
Date of Response: 05/12/2025
View Response: 10808.pdf
Freedom of Information Request Reference: 10807
Date Received: 05/11/2025
Summary:
Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?
Date of Response: 04/12/2025
View Response: 10807.pdf
Freedom of Information Request Reference: 10806
Date Received: 05/11/2025
Summary:
Medical records / Digital Forms / Storage 1. Have you yet to start, partly started or completed scanning your medical records? 2. If started or completed, was this handled in-house or by an external company? If yes, please name the supplier 3. Have you digitalised all your forms and are running a PiP (Paperless in Patient) approach (from the point of patient presentation to them leaving are all patient records digitalised)? 4. If you are not using a PiP approach, do you scan your end of episode material? 5. Do you store medical records on site or is this handled off site by an external company? If yes, please name supplier 6. Do you use a digital HR staff onboarding and administration system that interfaces with ESR to support HR processes and workflows? Finally, who at the Trust is responsible for these arrangements?
Date of Response: 27/11/2025
View Response: 10806.pdf
Freedom of Information Request Reference: 10805
Date Received: 05/11/2025
Summary:
Print Room 1. Do you have a print room equipped with one/more high-speed production device/s to handle large volume printing? 2. Is this run by your own staff or outsourced to a third-party provider? 3. If run internally, how many full-time equivalent (FTE) run this facility? 4. Number of devices & model type/s? 5. Name of incumbent supplier? 6. Contract start / end date and length of any option to extend? 7. If outsourced, please advise contract start / end date and length of any option to extend? 8. Was this contract awarded through a framework? If yes, which one used? 9. Annual spend (ex VAT) covering equipment & staff costs or total outlay if this service is outsourced External Print 1. Do you outsource any print requirement to an external supplier/s (for example to print forms, booklets, leaflets, manuals, posters, banners etc)? 2. Name of incumbent supplier/s? 3. If this arrangement provided under contract, please advise start / end date and length of any option to extend? 4. Was this contract awarded through a framework? If yes, which one used? 5. Alternatively, was this awarded through a DPS arrangement? 6. Annual spend (ex VAT) for this service over the past 12 months? Mail Room (Inbound and/or Outbound) 1. Do you have your own in-house Mail Room operation? 2. If yes, how is the service run - physical or digital mail distribution? 3. Is this run by your own staff or outsourced to a third-party provider? 4. If run by your own staff, how many full-time equivalent (FTE) staff run this facility? 5. If outsourced, please advise name of current provider, contract start / end date and length of any option to extend? 6. Was this contract awarded through a framework? If yes, which one used? 7. Annual spend (ex VAT) covering running and staff costs or total outlay if this service outsourced? 8. Do you use a Hybrid Mail service as part of your patient communications approach? 9. If yes, please (a) name supplier (b) contract start / end date (c) framework through which this awarded? Finally, who at the Health Board is responsible for these arrangements?
Date of Response: 11/12/2025
View Response: 10805.pdf
Freedom of Information Request Reference: 10804
Date Received: 05/11/2025
Summary:
• The number of people currently being prescribed methadone by the NHS as of 5 November 2025. • The number of people who were being prescribed methadone on 5 November in each of the years 2021, 2022, 2023, and 2024. For example, X many people were being prescribed methadone on 5 November 2024, etc. If this is not possible, please instead provide it for the calendar year overall. • The cost to the NHS of prescribing methadone in each calendar year 2021, 2022, 2023, 2024, and 2025 to 5 November 2025.
Date of Response: 04/12/2025
View Response: 10804.pdf
Freedom of Information Request Reference: 10803
Date Received: 05/11/2025
Summary:
Please provide the data for the months of August 2025, September 2025, and October 2025 covering the following staff groups: • Midwives • Paediatric Nurses • Neonatal Intensive Care Unit (NICU) Nurses For each of these three months, please provide: 1. Total number of agency hours worked for each staff group. 2. Total agency spend (£) for each staff group. 3. Average charge rate (£ per hour) paid for each staff group.
Date of Response: 01/12/2025
View Response: 10803.pdf
Freedom of Information Request Reference: 10802
Date Received: 05/11/2025
Summary:
I would like to submit a Freedom of Information (FOI) request for the following data for Western General Hospital relating to Pompe disease for the period 1 July 2025 to 30 September 2025. For reference, Pompe disease may be coded under: * ICD-10: E74.0 (Glycogen storage disease), or more specifically noted as Acid Maltase Deficiency / Pompe disease * SNOMED CT Concept ID: 86651009 - Glycogen storage disease type II (Pompe disease) If exact matches are unavailable, please provide the nearest equivalent coding used by your Trust and specify the codes applied. Table 1 - Patients Treated and Diagnosed (Jul-Sep 2025)) Product Number of Patients Treated Number of Patients Diagnosed with Pompe (ICD-10 E74.0 / SNOMED 86651009) Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 2 - Patients Treated and Volume Used (Jul-Sep 2025) Product Volume Used (IUs or mg) Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 3 - New Patients Treated by Product (Jan-Mar 2025) Product July 2025 August 2025 September 2025 Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti) Table 4- Patients Treated by Age Group and by Product (Jul-Sep 2025) Product Age Group Number of patients treated Avalglucosidase Alfa (Nexviazyme) 0-11 12-17 18+ Alglucosidase Alfa (Myozyme) 0-11 12-17 18+ Cipaglucosidase Alfa + Miglustat (Pombiliti) 0-11 12-17 18+ Table 5: Naïve (New Start) and Switch Patients by Product (Jul-Sep 2025) Product Number of Naïve (New Start) Patients Number of Patients Switching To this Product Number of Patients Switching From this Product Avalglucosidase Alfa (Nexviazyme) Alglucosidase Alfa (Myozyme) Cipaglucosidase Alfa + Miglustat (Pombiliti)
Date of Response: 07/11/2025
View Response: 10802.pdf
Freedom of Information Request Reference: 10801
Date Received: 05/11/2025
Summary:
1. The number of unique patients with a recorded diagnosis of Primary Immunodeficiency (PID) in Q3'25(July, August, and September 2025) a. Of these PID patients, what is the number of PID patients treated with Immunoglobulin in Q3'25(July, August, and September 2025)If possible, segment patients by brand used e.g 5 patients on Cuvitru b. How of these Ig treated PID patients are naïve (new starts) in Q3'25(July, August, and September 2025)? 2. The number of unique patients with a recorded diagnosis of Secondary Immunodeficiency (SID) in Q3'25(July, August, and September 2025) a. Of these SID patients, what is the number of SID patients treated with Immunoglobulin Q3'25(July, August, and September 2025) If possible, segment patients by brand used? b. How of these Ig treated SID patients are naïve (new starts) in Q3'25(July, August, and September 2025)? 3. The number of unique patients with a recorded diagnosis of Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Q3'25(July, August, and September 2025) a. Of these SID patients, what is the number of CIDP patients treated with Immunoglobulin Q3'25(July, August, and September 2025) If possible, segment patients by brand used? b. How of these Ig treated CIDP patients are naïve (new starts) in Q3'25(July, August, and September 2025)? 4. Definition: (ICD Codes) For reference, the following ICD-10 codes apply to the indications listed above: Primary Immunodeficiency (PID): D80 (Immunodeficiency with predominantly antibody defects) Secondary Immunodeficiency (SID):  • D84.81 (Immunodeficiency due to conditions classified elsewhere)  • D84.821 (Immunodeficiency due to drugs)  • D84.822 (Immunodeficiency due to external causes)  • D84.9 (Immunodeficiency, unspecified) Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): G61.8 (Other inflammatory polyneuropathies) 5. The number of immunoglobulin vials/volume in grams distributed to NHS Lothian in each month for July, August, and September 2025, broken down by product (see below). I would also like to request the number of patients NHS Lothian by brand if available * Vigam * Flebogamma DIF * Gammaplex * Gamunex-C * Octagam * Gamten * Kiovig * Intratect * Privigen * Iqymune * Gammanorm * Subcuvia * Subgam * Hizentra * Hyqvia * Cuvitru * Panzyga * Xembify * Cutaquig * Yimmugo • Vyvgart (Efgartigimod) (if available)
Date of Response: 04/12/2025
View Response: 10801.pdf
Freedom of Information Request Reference: 10800
Date Received: 04/11/2025
Summary:
1. How much has been incurred to date in relation to the planned National Treatment Centre in your health board, which is currently paused 2. In relation to Q1, how much has been incurred in each of the following financial years: 2024/25 and 2025/26 (most recent)
Date of Response: 27/11/2025
View Response: 10800.pdf
Freedom of Information Request Reference: 10799
Date Received: 04/11/2025
Summary:
1. Can you confirm if your health board carries out any training related to diversity, equality, and inclusion matters? 2. Please can you provide a breakdown of what the training in (1): a. Involves b. What subjects/topics/module the training relates to c. How much time is spent on each subject/topic/module d. The cost of each module 3. Please can you outline who is required to take this training? 4. What is the total cost of this training?
Date of Response: 03/12/2025
View Response: 10799.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS